American Journal of Clinical Dermatology

, Volume 14, Issue 2, pp 147–153 | Cite as

The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects

A Randomized, Placebo-Controlled Study
  • Yuan Wang
  • Mei WangEmail author
  • Shengxiang Xiao
  • Ping Pan
  • Ping Li
  • Jia Huo
Original Research Article



Argireline is a synthetic peptide that is patterned from the N-terminal end of the protein SNAP-25 and has been shown to reduce the degree of facial wrinkles. It is reported to inhibit vesicle docking by preventing formation of the ternary SNARE complex and by interfering in catecholamine release. The anti-wrinkle efficacy of argireline has not been studied in Chinese subjects.


The objective of the study was to evaluate the safety and efficacy of argireline in the treatment of peri-orbital wrinkles in Chinese subjects.


A total of 60 subjects received a randomized treatment of argireline or placebo in a ratio of 3:1. Argireline or placebo was applied to their peri-orbital wrinkles twice daily for 4 weeks, and then evaluations were made for the improvements in wrinkles. In the subjective evaluation, Daniell’s classification and Seeman’s standard were applied to make a global assessment of changes in the appearance of peri-orbital lines. In the objective evaluation, silicone replicas of the skin at the application area were made before and after the treatment, which were analyzed by a wrinkle-analysis apparatus.


In the subjective evaluation, the total anti-wrinkle efficacy in the argireline group was 48.9 %, compared with 0 % in the placebo group. In the objective evaluation, the parameters of roughness were all decreased in the argireline group (p < 0.01), while no decrease was obvious in the placebo group (p > 0.05).


This study showed that argireline had a significant anti-wrinkle effect in Chinese subjects.


Chinese Subject Snare Complex Facial Wrinkle Dependent Exocytosis Silicone Impression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



There were no sources of funding received to prepare this study. The authors have no conflicts of interest in the contents of this study.


  1. 1.
    Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20:343–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31:832–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Gutierrez LM, Cannes JM, Ferrer-Monteil AV, et al. A peptide that mimics the carboxy-terminal domain of SNAP-25 blocks Ca2+-dependent exocytosis in chromaffin cells. FEBS Lett. 1995;372:39–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Gutierrez LM, Viniegra S, Reuda J, et al. A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J Biol Chem. 1997;272:2634–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Blanes-Mira C, Clementey J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24:303–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Yamauchi P, Lowe N. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22:34–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Vartanian AJ, Dayan SH. Facial rejuvenation using botulinum toxin A: a review and updates. Facial Plast Surg. 2004;20:11–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Daniell HW. Smoker’s wrinkles: a study in the epidemiology of “crow’s feet”. Ann Intern Med. 1971;75(6):873–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Seeman D, Alster TS. Combination radiofrequency and diode laser for treatment of facial rhytides and skin laxity. Cosmet Laser Ther. 2005;7:11–5.CrossRefGoogle Scholar
  10. 10.
    Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C botulinum A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg. 2008;32:724–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Fagien S, Cox SE, Finn JC, et al. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33(1 Spec No.):S2–9.Google Scholar
  14. 14.
    Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297–303.PubMedCrossRefGoogle Scholar
  15. 15.
    Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414–22 (discussion 422).Google Scholar
  16. 16.
    Carruthers JD, Lowe NJ, BoNTA Glabellar Lines II Study Group, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089–98.PubMedGoogle Scholar
  17. 17.
    American Society for Aesthetic Plastic Surgery. 11.5 million cosmetic procedures in 2006. 2007 [online]. Available from URL: [Accessed 2008 Jul 28].
  18. 18.
    Benedetto AV. The cosmetic use of botulinum neurotoxin type A. Int J Dermatol. 1999;38:641–55.PubMedCrossRefGoogle Scholar
  19. 19.
    Becker-Wegerich PM, Rauch L, Ruzicka T. Botulinum toxin: a successful decollete rejuvenation. Dermatol Surg. 2002;28:168–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Frankel AS. Botox for rejuvenation of the periorbital region. Facial Plast Surg. 1999;15:255–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature’s most toxic proteins. Annu Rev Microbiol. 1999;53:551–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen YA, Scheller RH. SNARE-mediated membrane fusion. Nat Rev Mol Cell Biol. 2001;2:98–106.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Yuan Wang
    • 1
  • Mei Wang
    • 1
    Email author
  • Shengxiang Xiao
    • 1
  • Ping Pan
    • 1
  • Ping Li
    • 1
  • Jia Huo
    • 1
  1. 1.The Second Hospital of Xi’an Jiaotong UniversityXi’anChina

Personalised recommendations